FARXIGA PATENTS FACING OPPOSITIONS
FARXIGA facing oppositions at the European Patent Office (EPO)
| Patent Number | Title | Applicants | Legal Status | Legal Status Date | Oppositions | Activity Alert |
|---|---|---|---|---|---|---|
| EP2347762B1 | Exendin for treating diabetes and reducing body weight | Revoked | Dec 15, 2023 |
INSTONE, TERRY/APPLEYARD LEES IP/READ, HOWARD
GENERICS
| ||
| EP2508188B1 | Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate | Granted and Under Opposition | Apr 07, 2023 |
WUESTHOFF & WUESTHOFF
GALENICUM
KRAUS & LEDERER
GENERICS
GEDEON RICHTER
| ||
| EP2409707B8 | Polymer-based sustained release device | Opposition rejected | Jan 20, 2023 |
PHARMATHEN
TEVA PHARMACEUTICAL
| ||
| EP1971362B1 | Exendin for treating diabetes and reducing body weight | Revoked | Jul 08, 2022 |
PHARMATHEN
GLAXO GROUP
PENTAFARMA, SOCIEDADE
COOLEY
GENERICS
TEVA PHARMACEUTICAL
| ||
| EP2069374B2 | Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes | Patent maintained as amended | Jun 25, 2021 |
LEK PHARMACEUTICALS
| ||
| EP2139494B1 | Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate | Granted and Under Opposition | Feb 07, 2020 |
ZENTIVA
GALENICUM
GENERICS
STADA-ARZNEIMITTEL
GEDEON RICHTER
KRAUS & WEISERT
| ||
| EP3363807B1 | Pharmaceutical composition comprising crystalline (2s,3r,4s,5s,6r)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol (s)-propylene glycol solvate | Granted and Under Opposition | Oct 11, 2019 |
GENERICS
| ||
| EP3045466B1 | (2s,3r,4s,5s,6r)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-2-methoxy-tetrahydro-pyran-3,4,5-triol propylene glycol solvate as sgt2 inhibitor for the treatment of diabetes | Granted and Under Opposition | Nov 03, 2017 |
GENERICS
|